ʻO Daclatasvir Dihydrochloride
wehewehe
ʻO Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) he mea ikaika a hana waha.HCV NS5A pūmuamea hoʻopaneʻe meEC50s laula o 9-146 pM nomau genotypes HCV replicon.ʻO Daclatasvir dihydrochloride kekahiʻO ka anion organik e lawe ana i ka polypeptide 1B (OATP1B)aOATP1B3mea hoʻopaneʻe meIC50s o 1.5 µM a me 3.27 µM.
IC50& Pahuhopu
EC50: 50 pM (HCV replicon genotype 1a), 9 pM (HCV replicon genotype 1b), 71 pM (HCV replicon genotype 2a), 146 pM (HCV replicon genotype 3a), 12 pM (HCV replicon genotype 4a) a me HCV HCV replicon genotype 5a)[1]
Kd: 8 nM (NS5A33-202) a me 210 nM (NS5A26-202)[2]
IC50: 1.5 µM (OATP1B) a me 3.27 µM (OATP1B3)[3]
In Vitro
Hōʻike ʻo Daclatasvir (BMS-790052) i ka hana hoʻoneʻe ikaika i nā genotypes āpau i hoʻāʻo ʻia, me EC50mai 9 pM a 146 pM.Kāohi ʻo Daclatasvir i ka HCV replicon genotype 1a, 1b, 2a, 3a, 4a a me 5a me EC50nā waiwai o 50 pm, 9 pm, 71 pm, 146 pm, 12 pm a me 33 pm, kēlā me kēia.ʻO Daclatasvir kahi mea hoʻopaneʻe ikaika o ka JFH-1 genotype 2a maʻi maʻi maʻi e hoʻopili hou ana i ka moʻomeheu cell (EC50=28 pM)[1].Hoʻopaʻa paʻa ʻo Daclatasvir (BMS-790052) iā NS5A33-202 a me NS5A26-202 me Kds o 8 nM a me 210 nM[2].
Waihona
| Pauda | -20°C | 3 makahiki |
| 4°C | 2 makahiki | |
| I ka solvent | -80°C | 6 mahina |
| -20°C | 1 mahina |
ʻO ka hoʻokolohua lapaʻau
| Helu NCT | Kākoʻo | Kūlana | Lā Hoʻomaka | Māhele |
| NCT03369327 | Teheran University of Medical Sciences|RojanPharma Pharmaceutical Company | ʻO ka maʻi maʻi hepatitis C, pane i ka lāʻau lapaʻau o|Human Immunodeficiency Virus | Ianuali 1, 2017 | Māhele 3 |
| NCT03485846 | R-Pharm|Almedis | Hepatitis C Genotype 1b | Nowemapa 27, 2017 | Māhele 2 |
| NCT01016912 | Bristol-Myers Squibb | Ma'i Hepatitis C | Kekemapa 2009 | Māhele 2 |
| NCT01629732 | Bristol-Myers Squibb | Hepatitis C Virus | Malaki 2013 | Māhele 2 |
| NCT01497834 | Bristol-Myers Squibb | Hepatitis C | Ianuali 2012 | Māhele 3 |
| NCT01973049 | Bristol-Myers Squibb | Hepatitis C | Kekemapa 2013 | Māhele 3 |
| NCT00663208 | Bristol-Myers Squibb | ʻO ka maʻi Hepatitis C | Mei 2008 | Māhele 2 |
| NCT02576314 | Ke Keena Imi Kanaka a Ola Ola|Beijing 302 Hospital | Ma'i Hepatitis C mau | Mei 2015 | Māhele 3 |
| NCT02756936 | Ke kikowaena noiʻi maoli, ʻAigupita|Zeta Pharmaceutical Industries | Ola ola | Pepeluali 2016 | Māhele 1 |
| NCT02771405 | National Hepatology & Tropical Medicine Research Institute|Kairo University | ʻO ka maʻi maʻi maʻi C, ka maʻi maʻi|hepatocellular carcinoma | Malaki 2016 | Māhele 3 |
| NCT03706898 | Viriom | HIV-1-infection|Hinoʻino o ka maʻi hepatic | ʻOkakopa 1, 2018 | Māhele 1 |
| NCT02319031 | Bristol-Myers Squibb | Hepatitis C | Pepeluali 2015 | Māhele 3 |
| NCT02124044 | National Institute of Health Clinical Center (CC)|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb | HIV-HCV | Pepeluali 2014 | Māhele 2 |
| NCT02551861 | Bristol-Myers Squibb | Hepatitis C | Kekemapa 2015 | Māhele 2 |
| NCT00859053 | Bristol-Myers Squibb | Hepatic Insufficiency | Malaki 2009 | Māhele 1 |
| NCT01257204 | Bristol-Myers Squibb | Hepatitis C Virus | Kekemapa 2010 | Māhele 2 |
| NCT03063879 | Teheran University of Medical Science|Ahvaz Jundishapur University of Medical Science|Shiraz University of Medical Science|Hamadan University of Medical Science | ʻO ka maʻi maʻi maʻi C, ka maʻi | | ʻApelila 1, 2017 | Māhele 4 |
| NCT01017575 | Bristol-Myers Squibb | Ma'i Hepatitis C | Kekemapa 2009 | Māhele 2 |
| NCT02865369 | Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital | ʻO ka maʻi Hepatitis C | Kepakemapa 2016 |
|
| NCT04070235 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | ʻO ka maʻi maʻi maʻi C, maʻi maʻi | Malaki 29, 2019 | Māhele 2|Mahele 3 |
| NCT03487848 | Bristol-Myers Squibb | Hepatitis C|Ma'i ma'i ma'i ma'i | Mei 18, 2018 | Māhele 2 |
| NCT00904059 | Bristol-Myers Squibb | Hepatitis C | Mei 2009 | Māhele 1 |
| NCT02107365 | Ke Kula Nui o Palani no ka Noi'i Ola a Lapa'au-Palani National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | Nowemapa 2013 | Māhele 2 |
| NCT02397395 | ʻO Janssen R&D ʻIlelani | Hoʻopilikia i ka Renal|Ka maʻi Renal pae hope | Mei 2015 | Māhele 2 |
| NCT03169348 | Kulanui ʻo Assiut | Hepatitis C | Nowemapa 1, 2017 | Pili 'ole |
| NCT02323594 | Bristol-Myers Squibb | Ma'i Hepatitis C | Kekemapa 2014 | Māhele 1 |
| NCT03537196 | ʻO ke Keʻena Lapaʻau Palani no ka ʻImi Ola a me ka ʻImi Lapaʻau-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Hepatitis C|Hoʻohana lāʻau|Hepatitis C | Nowemapa 13, 2018 | Māhele 4 |
| NCT02103569 | Bristol-Myers Squibb | Hepatitis C | ʻApelila 2014 | Māhele 1 |
| NCT02772744 | Ke Kulanui ʻo Zagazig|Ke Kulanui ʻo Cairo | Hepatitis C | Nowemapa 1, 2017 |
|
| NCT01718158 | Bristol-Myers Squibb | Hepatitis C | Ianuali 2013 | Māhele 3 |
| NCT02496078 | Bristol-Myers Squibb | Hepatitis C | ʻAukake 2015 | Māhele 3 |
| NCT01425970 | Bristol-Myers Squibb | Hepatitis C | Mei 2012 | Māhele 2 |
| NCT01471574 | Bristol-Myers Squibb | Hepatitis C, Genotype 1 | Kekemapa 2011 | Māhele 3 |
| NCT01573351 | Bristol-Myers Squibb | Hepatitis C Virus | Mei 2012 | Māhele 3 |
| NCT01938625 | ʻO Janssen R&D ʻIlelani | ʻO ka maʻi maʻi maʻi C, maʻi maʻi | Kekemapa 12, 2013 | Māhele 2 |
| NCT01492426 | Bristol-Myers Squibb | Hepatitis C | Ianuali 2012 | Māhele 3 |
| NCT03480932 | Johns Hopkins Bloomberg School of Public Health|National Institute on Drug Abuse (NIDA)|YR Gaitonde Center for AIDS Research and Education | ʻO ka maʻi maʻi maʻi C, maʻi maʻi | Pepeluali 2, 2018 | Māhele 2|Mahele 3 |
| NCT03163849 | Kulanui ʻo Assiut | ʻO ka maʻi maʻi maʻi maʻi maʻi c | Sepatemaba 1, 2019 | Māhele 3 |
| NCT01581203 | Bristol-Myers Squibb | Hepatitis C Virus | Mei 2012 | Māhele 3 |
| NCT01492504 | Bristol-Myers Squibb | Hepatitis C | Pepeluali 7, 2012 |
|
| NCT03686722 | Mohamed Raslan|Ke Kulanui ʻo Ain Shams|Ke Keʻena Noiʻi Lapaʻau, Kairo, ʻAigupita | ʻO ka maʻi maʻi maʻi, ʻano 2| ʻo ka maʻi maʻi maʻi C| nā hui lāʻau | Kepakemapa 9, 2017 | Māhele 1 |
| NCT02262728 | ʻO Janssen Research & Development, LLC | ʻO ka maʻi maʻi maʻi C, maʻi maʻi | Kepakemapa 30, 2014 | Māhele 2 |
| NCT02349048 | ʻO Janssen Research & Development, LLC | Hepatitis C Virus | Ianuali 2015 | Māhele 2 |
| NCT03882307 | Kulanui ʻo Assiut | ʻO ka maʻi maʻi maʻi C, maʻi maʻi | Mei 2020 | Māhele mua 1 |
| NCT02758509 | Parc de Salut Mar | Hepatitis C|Cirrhosis | Ianuali 1, 2010 |
|
| NCT01795911 | Bristol-Myers Squibb | Hepatitis C | Malaki 2013 | Māhele 2 |
| NCT03549832 | Ke Kulanui ʻo Assiut|Ke Kulanui o Sohag|Ke Kulanui o South Valley | HCV Coinfection | Ianuali 1, 2018 | Pili 'ole |
| NCT02161939 | Bristol-Myers Squibb | ʻO ka maʻi Hepatitis C |
| |
| NCT01309932 | Bristol-Myers Squibb | Hepatitis C | Malaki 2011 | Māhele 2 |
| NCT01995266 | Bristol-Myers Squibb | Hepatitis C | Pepeluali 28, 2014 | Māhele 3 |
| NCT02640157 | AbbVie | Ma'i Hepatitis C|Ma'i Hepatitis C|Ma'i Hepatitis C Genotype 3 | Kekemapa 2015 | Māhele 3 |
| NCT02032875 | Bristol-Myers Squibb | Hepatitis C | Malaki 2014 | Māhele 3 |
| NCT02624063 | Ke Kulanui Federal o São Paulo | ʻO ka maʻi maʻi maʻi C, maʻi maʻi | Kekemapa 2015 | Māhele 4 |
| NCT00546715 | Bristol-Myers Squibb | ʻO ka maʻi Hepatitis C | Nowemapa 2007 | Māhele 1|Mahele 2 |
| NCT01718145 | Bristol-Myers Squibb | Ma'i Hepatitis C | Nowemapa 2012 | Māhele 3 |
| NCT01616524 | Bristol-Myers Squibb | Hepatitis C Virus (HCV) | Iulai 2012 | Māhele 3 |
| NCT02032901 | Bristol-Myers Squibb | Hepatitis C | Ianuali 2014 | Māhele 3 |
| NCT03540212 | Ke Kulanui ʻo Ain Shams | Ka ma'i HCV mau | Kekemapa 10, 2017 | Māhele 2|Mahele 3 |
| NCT02097966 | Bristol-Myers Squibb | ʻO ka maʻi Hepatitis C |
| |
| NCT02596880 | Ke Kulanui o ʻEpekema Lapaʻau ʻo Tehran | Hepatitis C|Cirrhosis | Kepakemapa 2015 | Māhele 3 |
| NCT04019717 | ʻO Atea Pharmaceuticals, Inc. | ʻO ka maʻi maʻi maʻi C|Maʻi maʻi maʻi maʻi C, maʻi maʻi maʻi maʻi maʻi maʻi C|Maʻi maʻi maʻi hepatitis C| | Iune 20, 2019 | Māhele 2 |
| NCT02992457 | Kulanui ʻo Tanta | Hepatitis C | Ianuali 2015 | Māhele 4 |
| NCT03547895 | Kulanui ʻo Zagazig | Decompensated Cirrhosis | Iune 1, 2015 | Pili 'ole |
| NCT03004625 | Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital | Hepatitis C | Nowemapa 2016 | Māhele 3 |
| NCT01051414 | Bristol-Myers Squibb | Ma'i Hepatitis C | ʻApelila 2010 | Māhele 2 |
| NCT02309450 | Ke Kula Nui o Palani no ka Noi'i Ola a Lapa'au-Palani National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | Kekemapa 2014 | Māhele 2 |
| NCT01628692 | Bristol-Myers Squibb|Janssen Research & Development, LLC | Hepatitis C Virus | Iulai 2012 | Māhele 2 |
| NCT03186313 | ʻO ka Halemaʻi Liver ʻAigupita|Wadi El Nil Hospital | Hepatitis C | Kepakemapa 2016 | Māhele 3 |
| NCT03063723 | Halemai Hoʻohui ʻekolu, ke Kulanui ʻo Sun Yat-Sen | ʻO ka Hepatitis C (Maʻi ʻino) | Ianuali 1, 2016 |
|
| NCT00983957 | Bristol-Myers Squibb | ʻO ka maʻi Hepatitis C | ʻOkakopa 2009 | Māhele 1 |
| NCT01725542 | Ke Kula Nui o Palani no ka Noi'i Ola a Lapa'au-Palani National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | HCV-HIV Hui-hui | Kekemapa 2012 | Māhele 2 |
| NCT02282709 | Kahua no ka ʻImi ʻĀpaʻa | ʻO ka maʻi Hepatitis C | Pepeluali 2014 | Māhele 3 |
| NCT02032888 | Bristol-Myers Squibb | Hepatitis C | Pepeluali 2014 | Māhele 3 |
| NCT03247296 | Kulanui MTI | Hepatitis C | Pepeluali 28, 2017 |
|
| NCT01389323 | Bristol-Myers Squibb | Hepatitis C | Kepakemapa 2011 | Māhele 3 |
| NCT02556086 | Bristol-Myers Squibb | Hepatitis C | Kekemapa 2015 | Māhele 2 |
| NCT01741545 | Bristol-Myers Squibb | Hepatitis C Virus | Malaki 31, 2013 | Māhele 3 |
| NCT01866930 | Bristol-Myers Squibb | Ma'i Hepatitis C mau | Iulai 11, 2013 | Māhele 3 |
| NCT02268864 | Janssen-Cilag International NV | ʻO ka maʻi maʻi maʻi C, maʻi maʻi | Ianuali 2015 | Māhele 2 |
| NCT01797848 | Bristol-Myers Squibb | Hepatitis C | Iune 2014 | Māhele 3 |
| NCT03166280 | Eman Sayed Hassan Abd Allah|Assiut University | Hepatitis C | Iune 2017 |
|
| NCT02159352 | Bristol-Myers Squibb | Hepatitis C | Iune 2014 | Māhele 1 |
| NCT01125189 | Bristol-Myers Squibb | Hepatitis C Virus | Iulai 2010 | Māhele 2 |
| NCT03748745 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Pilikia laau | Nowemapa 19, 2018 | Māhele 1 |
| NCT01012895 | Bristol-Myers Squibb | ʻO ka maʻi Hepatitis C | Kekemapa 2009 | Māhele 2 |
| NCT02565888 | Ke Kulanui ʻo Radboud | Hepatitis C|HIV | Nowemapa 2015 | Māhele 1 |
| NCT02555943 | Ke Keʻena Noiʻi Kanaka a Ola Ola|Beijing 302 Hospital|Hakapila ʻo Nanfang o ke Kulanui Lapaʻau Hema | ʻO ka maʻi maʻi maʻi maʻi maʻi C|ka maʻi maʻi HBV| | Pepeluali 2015 | Māhele 2|Mahele 3 |
| NCT02304159 | Tarek I. Hassanein, MD, FACP, FAG, AGAF|Keena noiʻi o Kaleponi Hema | Hepatitis C|Cirrhosis | Ianuali 2015 | Māhele 4 |
| NCT02580474 | Myeong Jun Song|Bristol-Myers Squibb|Hakapila Kula Nui o Soonchunhyang|Ke Kulanui o Dankook|Ka Halema'i Kula Nui o Chungnam|Ka Halema'i Kulanui o Konyang|Ka Halema'i Kula Nui o Eulji|Ka Halema'i o Saint Vincent, Korea|Ka Halema'i Kulanui o Konkuk|Ka Halemai o Cheongju St. Mary, Cheongju , Korea|Hakapila Hoʻokaʻawale|Hakapila ʻo Guro University Korea|Hakapila Nui ʻo Eulji|Ke Kulanui Katolika o Korea | Hepatitis C | Pepeluali 2016 | Māhele 4 |
| NCT02104843 | Bristol-Myers Squibb | Hepatitis C | ʻApelila 2014 | Māhele 1 |
| NCT01428063 | Bristol-Myers Squibb | Ma'i Hepatitis C | Kepakemapa 2011 | Māhele 2 |
| NCT02123654 | Bristol-Myers Squibb | Ma'i Hepatitis C | ʻApelila 2014 | Māhele 3 |
| NCT02565862 | Ke Kulanui ʻo Radboud | Hepatitis C|Diabetes Mellitus|Ke kū'ē i ka insulin | Ianuali 2016 | Māhele 1 |
| NCT04211844 | Ke Kulanui ʻo Ain Shams | ʻO ka maʻi Hepatitis C | ʻOkakopa 1, 2019 |
|
| NCT00874770 | Bristol-Myers Squibb | Ma'i Hepatitis C | Iune 2009 | Māhele 2 |
| NCT03883698 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | ʻAʻole hiki i ka ʻāʻī, ka maʻi maʻi|hepatitis C | Malaki 15, 2019 | Māhele 3 |
| NCT01448044 | Bristol-Myers Squibb | Hepatitis C | Kekemapa 2011 | Māhele 3 |
| NCT01359644 | Bristol-Myers Squibb|Pharmasset | ʻO ka maʻi Hepatitis C | Iune 2011 | Māhele 2 |
| NCT01842451 | Vertex Pharmaceuticals Incorporated | Hepatitis C|CHC|HCV|Hepatitis C | Iune 2013 | Māhele 2 |
| NCT02762448 | Halema'i Kaona o Tainan | Hepatitis c | Iulai 2016 |
|
| NCT02473211 | Ke Keena Imi Kanaka a Ola Ola|Beijing 302 Hospital | Ma'i Hepatitis C mau | Ianuali 2015 | Māhele 2|Mahele 3 |
| NCT01455090 | Bristol-Myers Squibb | ʻO ka maʻi Hepatitis C | Nowemapa 30, 2011 | Māhele 2 |
| NCT03490097 | Ke Kulanui ʻo Ain Shams | ʻO ka maʻi Hepatitis c|Metabolic Syndrome | Kekemapa 1, 2017 | Māhele 2|Mahele 3 |
| NCT01170962 | Bristol-Myers Squibb | Hepatitis C Virus | ʻAukake 2010 | Māhele 2 |
| NCT02333292 | Halemai Kula Nui o Valme|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias Halemai Nui Universitario de Alicante|Hospital Universitario Araba|Hospital University Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia de Cordoba|Hospital Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo| Navarra|Hospital Clinico Universitario San Cecilio|Hospital Universitario La Fe|Hospital General Universitario de Valencia|Hospital Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospital General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Hospital Vir de Carlos Haya Regional Universitario la Luz|Hospital General Universitario de Castellón|Hospital Parc Taulí, Sabadell | Ma'i Hepatitis C mau | Kekemapa 2014 |
|
| NCT03200184 | Ke Kulanui o ʻEpekema Lapaʻau ʻo Tehran | Hepatitis C | Kepakemapa 1, 2016 | Māhele 4 |
| NCT03188276 | Halemai Hoʻohui ʻekolu, ke Kulanui ʻo Sun Yat-Sen | ʻO ka maʻi Hepatitis C | Pepeluali 1, 2016 | Māhele mua 1 |
| NCT01830205 | Bristol-Myers Squibb | Hepatitis C | Kepakemapa 2012 | Māhele 1 |
Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6nā papahana ma lalo o ka ʻae ʻia.
Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.
Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.
Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kau inoa ʻana.
Kolea Countec Bottled Packaging Line
ʻO Taiwan CVC Bottled Packaging Line
ʻO Italia CAM Board Packaging Line
Mekini Fette Compacting German
ʻO Iapana Viswill Tablet ʻIke
Keena Mana DCS
Ka launa pū ʻana o ka honua
ʻO ka launa pū ʻana o ka hale
E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou
